Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers.

Translational neurodegeneration - 23 Jun 2020

Remnestål Julia, Öijerstedt Linn, Ullgren Abbe, Olofsson Jennie, Bergström Sofia, Kultima Kim, Ingelsson Martin, Kilander Lena, Uhlén Mathias, Månberg Anna, Graff Caroline, Nilsson Peter

Abstract excerpt

BACKGROUND: The clinical presentations of frontotemporal dementia (FTD) are diverse and overlap with other neurological disorders. There are, as of today, no biomarkers in clinical practice for diagnosing the disorders. Here, we aimed to find protein markers in cerebrospinal fluid (CSF) from patients with FTD, presymptomatic mutation carriers and non-carriers. METHODS: Antibody suspension bead arrays were used to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Frontotemporal Dementia

Share to Genetic Testing

Share to Heterozygote

Share to Pilot Projects

Share to Prodromal Symptoms

Source

Open in PubMed Open full text

Identifiers

PMID: 32576262
DOI: 10.1186/s40035-020-00198-y
PMCID: PMC7310563

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers.PMID 32576262Read ↗

A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study.Semantic proximity Read ↗

Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an updateSemantic proximity Read ↗

Fluid biomarkers in frontotemporal dementia: past, present and futureSemantic proximity Read ↗

Altered plasma protein profiles in genetic FTD - a GENFI study.Semantic proximity Read ↗

Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of Frontotemporal DementiaSemantic proximity Read ↗

Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomicsSemantic proximity Read ↗

Blood-based protein biomarkers in definite frontotemporal dementia: a case-control studySemantic proximity Read ↗

The Need for Biomarkers in the ALS–FTD Spectrum: A Clinical Point of View on the Role of ProteomicsSemantic proximity Read ↗

Recent advances in understanding frontotemporal degenerationSemantic proximity Read ↗

Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypesSemantic proximity Read ↗

Advances in the treatment and management of frontotemporal dementia.Semantic proximity Read ↗

Addressing inter-individual variability in CSF levels of brain-derived proteins across neurodegenerative diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.